Skip to main content
SpringerLink
Log in

Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

  • Review Article
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Colorectal cancer (CRC) is a leading tumour worldwide, and the median survival of metastatic patients with the latest therapeutic options today reaches 30 months. Therefore, it is important to plan a therapeutic strategy, able to optimize the use of the available drugs (fluoropyrimides, oxaliplatin, irinotecan and target biologic therapy), with the objective of maximizing the long-term efficacy, reducing toxicities and assuring better quality of life for the patients with mCRC. Among the most recently available drugs for the treatment of mCRC, aflibercept, a new antiangiogenetic agent, should be considered a promising therapeutical option for the second line setting. In this review, the mechanism of action and preclinical evidence, as well as pharmacological and clinical aspects of aflibercept will be analysed. In particular, this drug has a peculiar and unique mechanism of action, inhibiting VEGF-A, -B and PlGF pathways, which may help to overcome tumour escape mechanisms to bevacizumab treatment. From a clinical point of view, the addition of aflibercept to FOLFIRI regimen was able to significantly improve all the clinical outcome with respect to the chemotherapy alone in second line treatment of mCRC patients, regardless of age, RAS status, and prior use of bevacizumab. Finally, the safety profile of aflibercept is well known and manageable in most of the patients. Aflibercept can be considered a novel standard of care in the second line setting and an important therapeutic option for mCRC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.

    Article  CAS  PubMed  Google Scholar 

  2. I NUMERI DEL CANCRO IN ITALIA 2014. AIOM-AIRTUM; 2014.

  3. Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Supplement 3):iii1–9.

    Article  PubMed  Google Scholar 

  4. Linee guida AIOM. TUMORI DEL COLON RETTO. Edizione; 2014.

  5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer, version 2.2016.

  6. Giordano G, Febbraro A, Venditti M et al. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterology Research and Practice 2014, Article ID 526178, 13 pages.

  7. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis-dependent? J Pathol. 2004;202(1):5–13.

    Article  CAS  PubMed  Google Scholar 

  8. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–24.

    Article  CAS  PubMed  Google Scholar 

  9. Ferrarotto R, Hoff PM. Antiangiogenic drugs for colorectal cancer: exploring new possibilities. Clin Colorectal Cancer. 2013;12:1–7.

    Article  CAS  PubMed  Google Scholar 

  10. Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rodriguez M. Ziv-Aflibercept use in metastatic colorectal cancer. J Adv Pract Oncol. 2013;4(5):348–52.

    PubMed  PubMed Central  Google Scholar 

  12. Yang X, Zhang Y, Yang Y, et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 2013;110(34):13932–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012;30(32):4026–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kopetz S, Hoff PM, Morris JS. er al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453–9.

    Article  CAS  PubMed  Google Scholar 

  15. Loupakis F, Cremolini C, Fioravanti A, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104(8):1262–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ebos JM, Lee CR, Bogdanovic E, et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 2008;68(2):521–9.

    Article  CAS  PubMed  Google Scholar 

  17. Giampieri R, Scartozzi M, Del Prete M, et al. The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treat Rev. 2014;40(8):934–41.

    Article  CAS  PubMed  Google Scholar 

  18. Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biol: Targets Ther. 2014;8:13–25.

    CAS  Google Scholar 

  19. Dietvorst MHP, Eskens FALM. Current and novel treatment options for metastatic colorectal cancer: emphasis on aflibercept. Biol Ther. 2013;3:25–33.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Ther Adv Gastroenterol. 2013;6(6):459–73.

    Article  Google Scholar 

  22. Chiron M, Bagley RG, Pollard J, et al. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther. 2014;13(6):1636–44.

    Article  CAS  PubMed  Google Scholar 

  23. Chiron M, Bagley RG, Pollard J et al. Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer. In: Proceedings of the 2013 AACR-NCI-EORTC International Conference on Molecular Targets. Mol Cancer Ther. 2013;12(11 Suppl.):Abstract B2.

  24. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506.

    Article  PubMed  Google Scholar 

  25. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  26. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508.

    Article  CAS  PubMed  Google Scholar 

  27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.

    Article  CAS  PubMed  Google Scholar 

  28. Ruff P, Ferry DR, Lakom R, et al. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer. 2015;51:18–26.

    Article  CAS  PubMed  Google Scholar 

  29. Ruff P, Ferry DR, Papamichael D et al. Observed Benefit of Aflibercept in mCRC Patients ≥ 65 Years: Results of a Prespecified Age-Based Analysis of the VELOUR Study. Ann Oncol. 2013;24(4 Suppl.):iv11–iv24 (O-0017).

  30. Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50(2):320–31.

    Article  CAS  PubMed  Google Scholar 

  31. Hoff PM. The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression ≥ 9 months (mos) versus < 9 mos. J Clin Oncol. 2014;32:5s(Suppl; Abstract 3639).

  32. Mitchell E, Van Hazel G, Cunningham D et al. Evaluation of the Effect of Aflibercept (Z) on OS by Timing of 1st Line Disease Progression: A Post-Hoc Analysis of the VELOUR Trial. Ann Oncol. 2014;25(2 Suppl.):ii84 (P-0226).

  33. Van Cutsem E, Joulain F, Hoff PM et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016;11(3):383–400.

  34. Tabernero J, Macarulla T, Humblet Y et al. Aflibercept/FOLFIRI vs. Placebo/FOLFIRI in Metastatic Colorectal Cancer: A Post-Hoc Analysis of Median Overall Survival in VELOUR From the Retrospectively Assessed Time of Starting First-Line Treatment. Ann Oncol. 2014;25(2 Suppl.):ii14–ii104 (P-0288).

  35. Chau I, Joulain F, Iqbal SU, et al. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer. 2014;14:605.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Folprecht G, Pericay C, Saunders MP et al. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer – the AFFIRM study. Ann Oncol. 2016;27(7):1273–9.

  37. Sims T, Gao B, Phillips R, Lowy I. Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial. J Clin Oncol. 2015; 33 (suppl 3; abstr 638).

  38. Lambrechts D, Thienpont B, Thuillier, et al. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer. 2015;113(7):1027–34.

    Article  CAS  PubMed  Google Scholar 

  39. Frassineti L, Di Bartolomeo M, Heinemann V et al. Aflibercept+FOLFIRI for treatment of metastatic colorectal cancer after oxaliplatin failure:4th Interim Safety Data From the Global Aflibercept Safety and Quality-of-Life Program (ASQoP/AFEQT Studies). Ann Oncol. 2014;25(4 Suppl.):iv167–iv209 (528P).

  40. Iaffaioli VR, Pietrantonio F, Pastorino A et al. Aflibercept (afl) plus FOLFIRI for the 2nd-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): 4th interim safety data from the Italian cohort of the Aflibercept Safety and Quality-of-Life Program (ASQoP). AIOM 2014, Poster G14.

  41. Taieb J, Bordonaro R, Bencardino K et al. Quality of Life (QoL) on the Aflibercept/FOLFIRI Regimen: 4th Interim Analysis of the Global Aflibercept Safety and Health-Related QoL Program. Ann Oncol. 2014;25(4 Suppl.):iv167–iv209 (529P).

  42. Giampieri R, Caporale M, Pietrantonio F, et al. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? Crit Rev Oncol Hematol. 2016;100:99–106.

    Article  PubMed  Google Scholar 

  43. Cremolini C, Schirripa M, Antoniotti C, et al. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol. 2015;12(10):607–19. doi:10.1038/nrclinonc.2015.129.

    Article  CAS  PubMed  Google Scholar 

  44. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3 Suppl.):iii1–9.

  45. Echave M, Oyagüez I, Lamas MJ, et al. Aflibercept in combination with Folfiri in patients with metastatic colorectal cancer: cost-effectiveness based on velour best efficacy subgroup post-hoc analysis. Value Health. 2015;18(7):A454.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, University Hospital and University of Cagliari, Pole University Hospital “Duilio Casula” - S.S. 554, Km 4,500 Bivio per Sestu, 09042, Monserrato, CA, Italy

    Mario Scartozzi

  2. Sanofi Oncology External Innovation, Vitry-sur-Seine, France

    Loic Vincent

  3. Sanofi Oncology Translational Medicine, Vitry-sur-Seine, France

    Marielle Chiron

  4. Medical Oncology, University Hospital and University of Modena and Reggio Emilia, Modena, Italy

    Stefano Cascinu

Authors
  1. Mario Scartozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Loic Vincent
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marielle Chiron
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano Cascinu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Scartozzi.

Ethics declarations

Funding

This work was supported by an unrestricted grant from Sanofi.

Conflict of Interest

Mario Scatozzi and Stefano Cascinu have received honoraria from Sanofi for the preparation of this manuscript, for speaking at scientific meetings and participating in advisory boards.

Marielle Chiron has patents related to aflibercept and is an employee of and owns stock options in Sanofi. Loic Vincent is an employee of and owns stock in Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scartozzi, M., Vincent, L., Chiron, M. et al. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). Targ Oncol 11, 489–500 (2016). https://doi.org/10.1007/s11523-016-0447-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-016-0447-4

Keywords

Search

Navigation